Seeing Is Believing
Currently out of the existing stock ratings of David Turkaly, 136 are a BUY (96.45%), 4 are a HOLD (2.84%), 1 are a SELL (0.71%).
Analyst David Turkaly, currently employed at JMP, carries an average stock price target met ratio of 33.48% that have a potential upside of 28.88% achieved within 218 days.
David Turkaly’s has documented 279 price targets and ratings displayed on 19 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on STE, STERIS plc at 18-Nov-2024.
Analyst best performing recommendations are on NVTR (NUVECTRA).
The best stock recommendation documented was for STIM (NEURONETICS) at 1/8/2021. The price target of $15 was fulfilled within 11 days with a profit of $2.11 (16.37%) receiving and performance score of 14.88.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
3 months 10 days ago
(16-Sep-2024)
3/3 (100%)
$1.8 (21.95%)
243
Buy
$4.5
$2.93 (186.62%)
$3
1 years 4 months 15 days ago
(11-Aug-2023)
14/16 (87.5%)
$-0.55 (-10.89%)
297
Buy
$9
$7.43 (473.25%)
$6
1 years 6 months 11 days ago
(15-Jun-2023)
2/3 (66.67%)
$2.05 (29.50%)
81
Buy
$17
$15.43 (982.80%)
$12
2 years 5 months 7 days ago
(19-Jul-2022)
0/2 (0%)
$8.43 (98.37%)
Which stock is David Turkaly is most bullish on?
Which stock is David Turkaly is most reserved on?
What Year was the first public recommendation made by David Turkaly?